In exchange, they have agreed to make payments of up to $6 billion to thousands of plaintiffs in now-suspended lawsuits.
The ruling was part of a court review of a bankruptcy restructuring plan for Purdue, which filed for Chapter 11 protection in September 2019.
Companies in bankruptcy customarily get protection from legal claims; owners who have not filed for personal bankruptcy usually do not.
When the company filed for bankruptcy, the Sacklers faced about 400 lawsuits over their role in Purdue’s opioid business.
Legal experts say that the ruling, by the United States Court of Appeals for the Second Circuit, has implications for the Purdue case specifically and for owners of companies seeking bankruptcy generally.
Persons:
Sackler
Organizations:
Purdue Pharma, Purdue, Companies, United States, Appeals, Second Circuit